ID   HEY-T30
AC   CVCL_2Z96
DR   ATCC; CRL-3252
DR   cancercelllines; CVCL_2Z96
DR   Wikidata; Q54883217
RX   PubMed=20404007;
CC   Population: Caucasian.
CC   Doubling time: ~18-22 hours (ATCC=CRL-3252).
CC   Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Glu (c.1391G>A); ClinVar=VCV000013964; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): ATCC=CRL-3252
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 11
ST   D16S539: 8,12
ST   D5S818: 11,12
ST   D7S820: 12
ST   TH01: 8,9.3
ST   TPOX: 11
ST   vWA: 16,17
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0297 ! HEY
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-09-15; Last updated: 02-05-24; Version: 14
//
RX   PubMed=20404007; DOI=10.1158/1078-0432.CCR-09-3233;
RA   Huang G.S., Brouwer-Visser J., Ramirez M.J., Kim C.H., Hebert T.M.,
RA   Lin J., Arias-Pulido H., Qualls C.R., Prossnitz E.R., Goldberg G.L.,
RA   Smith H.O., Horwitz S.B.;
RT   "Insulin-like growth factor 2 expression modulates taxol resistance
RT   and is a candidate biomarker for reduced disease-free survival in
RT   ovarian cancer.";
RL   Clin. Cancer Res. 16:2999-3010(2010).
//